{"id":58,"date":"2017-09-19T03:05:28","date_gmt":"2017-09-19T01:05:28","guid":{"rendered":"http:\/\/www.bioactivescreeninglibrary.com\/?p=58"},"modified":"2022-01-07T10:42:59","modified_gmt":"2022-01-07T02:42:59","slug":"biological-assays-employed-evaluation-inhibitory-potency-17b-hsd1","status":"publish","type":"post","link":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/2017\/09\/19\/biological-assays-employed-evaluation-inhibitory-potency-17b-hsd1\/","title":{"rendered":"The biological assays employed for the evaluation of inhibitory potency towards 17b-HSD1"},"content":{"rendered":"

In the case of IDO1, the promoter region has been well characterized and contains several cis-acting response elements that are involved in the up-regulation of the gene by cytokines, such as IFN-c, the most potent inducer of IDO activity, as well as TNF-a . Two Interferon-Stimulated Response Elements and three Gamma Activated Sequence located within the 1300-bp upstream of the ATG initiation codon appear to be critical for maximal IDO1 promoter activity, with a synergistic activation by IFN-c and TNF-a . In the present study, we identified a VNTR polymorphism in the IDO1 promoter region, consisting of a 24-bp repeat motif located 1.3-kb upstream of the ATG initiation codon. It was identified by a PCR-sequencing strategy applied to 41 DNA samples and allowed us to characterize two different alleles, named *V1 and *V2, that carry one or two repeats, respectively, the *V1 allele corresponding to the reference sequence listed in Genbank . This polymorphism appears to be common in Caucasians, the frequency of the *V1 allele being 46\ufffdC48% and that of the *V2 variant being 52\ufffdC54% in our study. No additional VNTR allele with more than two motif GSK1120212<\/a> repeats was identified. To assess the impact of the VNTR polymorphism on IDO activity, 47 males and 47 females from a cohort of 300 healthy Caucasian subjects were selected<\/a> based on their genotype, and their sera were analysed to determine Trp and Kyn concentrations. We first observed a significant lower serum Trp concentration in females compared to males, as reported previously in other studies . Furthermore, females with a *V2\/*V2 purchase SB203580<\/a> genotype displayed a significant and a trend toward lower serum Trp concentration compared to females with a *V1\/*V2 and *V1\/*V1 genotype, respectively. IDO is known to be induced by soluble hormones, such as human chorionic gonadotropin, prolactin and estrogens, supporting the hypothesis of a hormonal control of IDO expression . It can then be postulated that the VNTR polymorphism we identified has an effect on Trp metabolism under the influence of a female hormonal environment, which is partly supported by Carretti et al. who showed that circulating Trp concentration has cyclic variations throughout the menstrual cycle.<\/p>\n","protected":false},"excerpt":{"rendered":"

In the case of IDO1, the promoter region has been well characterized and contains several cis-acting response elements that are involved in the up-regulation of the gene by cytokines, such as IFN-c, the most potent inducer of IDO activity, as well as TNF-a . Two Interferon-Stimulated Response Elements and three Gamma Activated Sequence located within … Continue reading “The biological assays employed for the evaluation of inhibitory potency towards 17b-HSD1”<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/posts\/58"}],"collection":[{"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/comments?post=58"}],"version-history":[{"count":1,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/posts\/58\/revisions"}],"predecessor-version":[{"id":59,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/posts\/58\/revisions\/59"}],"wp:attachment":[{"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/media?parent=58"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/categories?post=58"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/tags?post=58"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}